HealthTell™, an early stage Life Sciences company, announced that Carolyn Compton, M.D., Ph.D. and Caren Mason have joined the company’s Board of Directors. Compton brings over 30 years of leadership in pathology and life sciences to HealthTell, while Mason will offer her 20 years of senior executive experience across the public and private sector, building companies in life sciences, diagnostics, and medical devices.
Dr. Caroyln Compton
“In creating HealthTell’s Board, our aim has been to include the voices of healthcare leaders from across both academia and industry,” said Bill Colston, Ph.D., CEO of HealthTell. “As innovators in the life sciences and diagnostics space, we are honored to have both Dr. Compton and Caren Mason join our team. Together they offer a diverse and complementary perspective to working in the dynamic healthcare environment. We look forward to benefiting from their judgment and counsel.”
Having earned her M.D. and Ph.D. from Harvard Medical School, Compton is the Chief Medical Officer of the National Biomarkers Development Alliance at Arizona State University (ASU) and a professor of life sciences at ASU. She is a professor of laboratory medicine and pathology at the Mayo Clinic Medical School and an adjunct professor of pathology at both Johns Hopkins and theUniversity of Arizona. She previously held a position as professor of pathology at Harvard Medical School and Massachusetts General Hospital. She was also Chair of Pathology at McGill University, and Director of the Office of Biorepositories and Biospecimen Research at the National Cancer Institute for seven years.
“HealthTell’s diagnostic technology holds the potential to bring accurate and affordable diagnostic testing into a new era,” said Dr. Compton. “It’s been exciting to watch the company grow from the lab at Arizona State University, into an Immunosignature Technology company that can transform how we detect a person’s real-time response to chronic disease.”
Caren Mason joins the board from Verinata Health as the former CEO, where she designed and delivered the complete go-to-market strategy and commercial plan. Verinata was acquired by Illumina in 2013. Prior to Verinata, she served as CEO of Quidel (QDEL), and led a strong period of growth and profitability for the company. She is currently on the STAAR Surgical (STAA) board and was previously on the boards of Verinata, Quidel, MiraMedica, eMed Technologies and AdvaMed.
“HealthTell has created one of the most exciting technologies I have encountered, which has significant promise to change the way chronic illness is both detected and monitored,” said Mason. “I am looking forward to being a part of this important development that will impact the value of diagnostics for clinicians and patients throughout the continuum of care.”
HealthTell is an early stage Life Sciences company that utilizes an Immunosignature™ Technology for accurate and timely detection and monitoring of more than 30 progressive diseases. Based on robust, proprietary technology, the company is developing the first and only diagnostic platform capable of assessing an individual’s immune system response to specific diseases. This disruptive technology enables physicians to detect the presence or absence of a disease in its earliest stage, improving patient outcomes and reducing healthcare expenditures. Applicable to a broad range of therapeutic areas, HealthTell is empowering physicians and patients to proactively manage one’s health and make more informed decisions. For more information, please visit: http://www.healthtell.com/.